Acelyrin, Inc. (SLRN)
- Previous Close
2.4800 - Open
2.5200 - Bid 2.0700 x 200
- Ask 2.1600 x 200
- Day's Range
2.1100 - 2.5613 - 52 Week Range
1.8450 - 7.2500 - Volume
1,542,569 - Avg. Volume
1,446,645 - Market Cap (intraday)
213.505M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5000 - Earnings Date May 13, 2025 - May 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
www.acelyrin.comRecent News: SLRN
View More
Performance Overview: SLRN
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLRN
View MoreValuation Measures
Market Cap
249.76M
Enterprise Value
-191.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.54
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.73%
Return on Equity (ttm)
-44.54%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-248.23M
Diluted EPS (ttm)
-2.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
447.88M
Total Debt/Equity (mrq)
1.59%
Levered Free Cash Flow (ttm)
-216.69M